URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

M. Alice Rudolph

TitleResearch Assistant Professor
InstitutionSchool of Medicine and Dentistry
DepartmentNeurology in the Center for Human Experimental Therapeutics
Address
 
 Overview
NAME: Mary Alice Rudolph, PhD

HOME ADDRESS: 55 Branford Road
Rochester, New York 14618
Phone: (585) 244-5201

WORK ADDRESS: University of Rochester Medical Center
CHET/CTCC
265 Crittenden Blvd, CU 420694
Rochester, NY 14642-0694
Phone: (585) 275-0556
Fax: (585) 461-3554
Email: alice.rudolph@chet.rochester.edu

DATE AND PLACE OF BIRTH: February 12, 1947, Covington, Kentucky

CITIZENSHIP: USA

EDUCATION: 1987 PhD Community Health Education, Southern Illinois University,
Carbondale, Illinois
1979 MS Clinical Psychology, Eastern Kentucky University, Richmond, Kentucky
1969 BA Psychology, Thomas More College, Ft. Mitchell, Kentucky

 
 Selected Publications
List All   |   Timeline
  1. Dawson RJ, Benz J, Stohler P, Tetaz T, Joseph C, Huber S, Schmid G, Hügin D, Pflimlin P, Trube G, Rudolph MG, Hennig M, Ruf A. Structure of the acid-sensing ion channel 1 in complex with the gating modifier Psalmotoxin 1. Nat Commun. 2012; 3:936.
    View in: PubMed
  2. Kang UJ, Auinger P. Activity enhances dopaminergic long-duration response in Parkinson disease. Neurology. 2012 Apr 10; 78(15):1146-9.
    View in: PubMed
  3. Evatt ML, DeLong MR, Kumari M, Auinger P, McDermott MP, Tangpricha V. High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol. 2011 Mar; 68(3):314-9.
    View in: PubMed
  4. Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord. 2011 Mar; 26(4):608-13.
    View in: PubMed
  5. Kieburtz K. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial. Mov Disord. 2011 Jan; 26(1):37-44.
    View in: PubMed
  6. Simon DK, Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Nichols WC, Foroud T. Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. BMC Med Genet. 2010; 11:53.
    View in: PubMed
  7. Hauser RA, Auinger P, Oakes D. Levodopa response in early Parkinson's disease. Mov Disord. 2009 Dec 15; 24(16):2328-36.
    View in: PubMed
  8. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009 Dec; 66(12):1460-8.
    View in: PubMed
  9. Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Marder KS, Foroud T, Nichols WC. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology. 2009 Jul 28; 73(4):279-86.
    View in: PubMed
  10. Nichols WC, Kissell DK, Pankratz N, Pauciulo MW, Elsaesser VE, Clark KA, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T. Variation in GIGYF2 is not associated with Parkinson disease. Neurology. 2009 Jun 2; 72(22):1886-92.
    View in: PubMed
  11. Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, Foroud T. Clinical correlates of depressive symptoms in familial Parkinson's disease. Mov Disord. 2008 Nov 15; 23(15):2216-23.
    View in: PubMed
  12. Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology. 2009 Jan 27; 72(4):310-6.
    View in: PubMed
  13. Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 2008 Aug 12; 71(7):481-5.
    View in: PubMed
  14. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE. Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord. 2008 Apr 15; 23(5):653-9; quiz 776.
    View in: PubMed
  15. Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow WC, Shoulson I, Tandon PK. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008 Apr 15; 23(5):690-9.
    View in: PubMed
  16. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6):716-23.
    View in: PubMed
  17. Nichols WC, Elsaesser VE, Pankratz N, Pauciulo MW, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology. 2007 Oct 30; 69(18):1737-44.
    View in: PubMed
  18. Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter CA, Rudolph A, Shults CW, Wojcieszek J, Foroud T. R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation. Mov Disord. 2007 Jan 15; 22(2):254-7.
    View in: PubMed
  19. Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T, Nichols WC. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease. Mov Disord. 2006 Dec; 21(12):2257-60.
    View in: PubMed
  20. Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Wojcieszek J, Rudolph A, Shults CW, Foroud T, Nichols WC. Mutations in DJ-1 are rare in familial Parkinson disease. Neurosci Lett. 2006 Nov 20; 408(3):209-13.
    View in: PubMed
  21. Pankratz N, Byder L, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Mov Disord. 2006 Jan; 21(1):45-9.
    View in: PubMed
  22. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol. 2005 Oct; 252 Suppl 4:IV37-IV42.
    View in: PubMed
  23. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology. 2005 Jan 11; 64(1):87-93.
    View in: PubMed
  24. Nichols WC, Pankratz N, Hernandez D, Paisán-Ruíz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet. 2005 Jan 29-Feb 4; 365(9457):410-2.
    View in: PubMed
  25. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec 9; 351(24):2498-508.
    View in: PubMed
  26. Nichols WC, Uniacke SK, Pankratz N, Reed T, Simon DK, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T. Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. Mov Disord. 2004 Jun; 19(6):649-55.
    View in: PubMed
  27. Pankratz N, Uniacke SK, Halter CA, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC. Genes influencing Parkinson disease onset: replication of PARK3 and identification of novel loci. Neurology. 2004 May 11; 62(9):1616-8.
    View in: PubMed
  28. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology. 2004 Jan 27; 62(2):330-2.
    View in: PubMed
  29. Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, Shults CW, Conneally PM, Foroud T. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet. 2003 Oct 15; 12(20):2599-608.
    View in: PubMed
  30. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T. Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Hum Genet. 2003 Apr; 72(4):1053-7.
    View in: PubMed
  31. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C, Marder K, Conneally PM, Nichols WC. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology. 2003 Mar 11; 60(5):796-801.
    View in: PubMed
  32. Nichols WC, Pankratz N, Uniacke SK, Pauciulo MW, Halter C, Rudolph A, Conneally PM, Foroud T. Linkage stratification and mutation analysis at the Parkin locus identifies mutation positive Parkinson's disease families. J Med Genet. 2002 Jul; 39(7):489-92.
    View in: PubMed
  33. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet. 2002 Jul; 71(1):124-35.
    View in: PubMed
  34. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002 May; 51(5):604-12.
    View in: PubMed
  35. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001 Aug 14; 57(3):397-404.
    View in: PubMed
  36. Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord. 2001 Jan; 16(1):135-9.
    View in: PubMed
  37. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Parkinson Study Group. Neurology. 2000 Nov 28; 55(10):1540-7.
    View in: PubMed
  38. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med. 1999 Mar 11; 340(10):757-63.
    View in: PubMed
  39. Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Ann Neurol. 1998 Sep; 44(3 Suppl 1):S160-6.
    View in: PubMed
  40. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group. Ann Neurol. 1998 Mar; 43(3):318-25.
    View in: PubMed
  41. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. JAMA. 1997 Jul 9; 278(2):125-30.
    View in: PubMed
  42. Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group. Ann Neurol. 1996 Jul; 40(1):99-107.
    View in: PubMed
  43. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol. 1996 Jan; 39(1):37-45.
    View in: PubMed
  44. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group. Ann Neurol. 1996 Jan; 39(1):29-36.
    View in: PubMed
  45. Kieburtz K, McDermott M, Como P, Growdon J, Brady J, Carter J, Huber S, Kanigan B, Landow E, Rudolph A, et al. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group. Neurology. 1994 Sep; 44(9):1756-9.
    View in: PubMed
  46. A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Parkinson Study Group. Ann Neurol. 1993 Apr; 33(4):350-6.
    View in: PubMed
  47. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol. 1989 Oct; 46(10):1052-60.
    View in: PubMed
  48. Rudolph A, McDermott RJ. The breast physical examination. Its value in early cancer detection. Cancer Nurs. 1987 Apr; 10(2):100-6.
    View in: PubMed
  49. Rudolph A, McDermott RJ, Gold RS. Use of statistics in the Journal of School Health 1979-1983: a content analysis. J Sch Health. 1985 Aug; 55(6):230-3.
    View in: PubMed

Visualizations


Rudolph's Networks

Concepts
_
Co-Authors
_
Similar People
_
Same Department